The market prospect of the most gunpowder packagin

  • Detail

The market prospect of pharmaceutical packaging materials is attractive

at a recent domestic packaging materials exhibition, pujinbo, deputy general manager of Nanfang Packaging Co., Ltd., revealed to the company that the company learned from the world's three major pet (polyethylene terephthalate) production line suppliers that by the end of 2003, China's pharmaceutical packaging material manufacturers and their raw material suppliers had ordered 24 PET production lines from the above three companies. This number seems small, but it is actually quite amazing, because PET film is the main raw material of composite film for pharmaceutical packaging, and launching a large PET production line costs tens of millions of dollars at any time. "No enterprise dares to invest money in it easily, which shows how attractive the potential of China's pharmaceutical packaging industry is."

according to experts, the contribution rate of pharmaceutical packaging materials to the pharmaceutical industry in China is low: in developed countries, pharmaceutical packaging has accounted for about 30% of the value of drugs, while this proportion in China is less than 10%, and there is considerable room for growth. In addition, new dosage forms of drugs are emerging one after another, and the matching drug packaging materials are still relatively slow to follow up, which has great potential to be tapped

China's pharmaceutical production industry is very large, and the demand for pharmaceutical packaging materials is naturally great. However, for a long time, China's pharmaceutical packaging production industry has been in a state of chaos, with backward technology and low production capacity. Half or even half of the production enterprises have not been able to deburr with sandpaper and oilstone mill; If the rising position exceeds the limit and the production standard is tilted, the pharmaceutical packaging industry has also ushered in its own "spring" while the pharmaceutical industry carries out GMP certification

the current situation is worrying and the dross needs to be discarded

although the development potential of China's pharmaceutical packaging industry is great, the backwardness of packaging materials and market chaos are also quite serious. In particular, compared with the emerging new dosage forms, the matching drug packaging, SABIC pp514m12, is too slow to follow up and is far from meeting the requirements of new drug development

the latest investigation by the State Food and Drug Administration found that the overall technical level of China's pharmaceutical packaging material industry is far behind that of developed countries. Among them, two indicators are sufficient to explain that the drug packaging, which accounts for about 65% of the total amount of preparations, has not reached the international level in the 1980s; The quality of packaging materials and the contribution rate of packaging to the pharmaceutical industry are low

Du ye, manager of the R & D Department of a biological products company in Guangzhou, said that since most of the existing pharmaceutical packaging material production enterprises in China are township collective enterprises with small scale and low level of equipment, technology and management, in order to reduce product costs, they secretly buy a large number of low-cost and low-quality products. For example, if the same composite membrane is produced in the clean workshop according to the regulations, the cost is about 22000 yuan/ton; However, those produced in the "underground factory" cost no more than 18000 yuan/ton

Mr. Lin of Nanfang Packaging Co., Ltd. added that there was an urgent need for the state to introduce measures to raise the threshold of the pharmaceutical packaging industry and shut out illegal manufacturers

seven pharmaceutical packaging materials enterprises propose to implement GMP certification

recently, seven enterprises, including Shanghai Haichang medical plastic factory, Jiangsu Lianyungang Zhongjin pharmaceutical packaging Co., Ltd. and Tianjin Boli Pharmaceutical Packaging Technology Co., Ltd., jointly called for the implementation of GMP certification system in the national pharmaceutical packaging materials industry as soon as possible, so as to strengthen management, standardize behavior and promote the healthy development of the industry. At the same time, they also proposed to colleagues to standardize enterprise management in strict accordance with the requirements of the drug administration law and the measures for the administration of drug packaging materials and containers issued by the State Food and drug administration; Actively respond to the requirements of the "Tenth Five Year Plan" for the development of pharmaceutical packaging, strengthen scientific and technological progress, and strive to develop new technologies and products of pharmaceutical packaging materials to meet the pharmaceutical demand for pharmaceutical packaging products; Based on the national physical and chemical indicators related to drug packaging materials, starting from raw materials, control product quality and better serve the pharmaceutical industry; Put an end to the use of waste and recycled materials to ensure the safety of drug packaging products

the measures for the administration of pharmaceutical packaging materials and containers issued by the State Food and Drug Administration on April 29, 2004 has effectively promoted the orderly development of China's pharmaceutical packaging materials market and led to the process of the overall standardized development of the industry. However, due to the differences in the implementation standards of the "measures" across the country, a considerable number of enterprises still fail to meet the standards, and Some unlicensed enterprises are still producing and selling drug packaging materials. With the completion of GMP certification work in drug manufacturing enterprises, drug manufacturing enterprises have put forward higher quality requirements for drug packaging products. Therefore, purifying the industry environment, strengthening self-discipline and improving product quality have become the top priority to ensure the healthy development of the industry

in developed countries, pharmaceutical packaging accounts for 30% of the value of drugs, while in China it is less than 10%. Moreover, the survey from the State Drug Administration shows that the overall level of China's pharmaceutical packaging industry is not high and the grade is low. According to experts' prediction, the next five years will be a period of rapid development of China's pharmaceutical packaging industry. Domestic enterprises see huge benefits, and have invested heavily in building GMP workshops to enter the pharmaceutical packaging market. In the past two years alone, more than 15 GMP production workshops have been newly built, not including the drug packaging projects of Jiangyin Shenda and Shanghai Zijiang. This year, Wuxi Huanyu invested another US $26.8 million to build a drug packaging material production enterprise with an annual output of 25000 tons. With the production of these powerful enterprise projects, it is bound to break the relatively stable market share of drug packaging materials for many years in the past two years and rapidly improve the overall production level of drug packaging materials in China

attractive market prospect

"the prospect of drug packaging material industry is very attractive". Some experts predict that the next five years will be a critical period for the rapid development of China's pharmaceutical packaging industry. At present, the annual output value of China's pharmaceutical packaging industry is about 15billion yuan, which can only meet about 80% of the needs of domestic pharmaceutical enterprises. According to the development speed of China's pharmaceutical industry in recent years, the annual GDP of pharmaceutical packaging materials will quickly exceed 20billion yuan in a short time

according to Chen Dengxiang, who is specially responsible for the preliminary examination of drug packaging materials registration in the drug registry of Guangdong food and drug administration, China has implemented the registration system for drug packaging materials since 2000. In more than three years, more than 740 varieties have passed the review and registration of the former State Drug administration, of which more than 100 are in Guangdong Province, ranking first in all provinces and cities

the rapid development of the pharmaceutical packaging material industry in recent years is obvious to all in the industry. However, it is also for this reason that some software conditions supporting this pharmaceutical peripheral industry have lagged behind, unable to keep up with its development pace. In the interview, it was found that there was a lack of accurate statistics on the current overall pattern of the domestic pharmaceutical packaging industry. Another serious problem is that the compatibility test between new pharmaceutical preparations and new packaging materials needs to be improved in China. Pu Jinbo said, "such tests are generally conducted by us for customers now, and their cycle is not

very long, and the human and material resources are also invested greatly." It is reported that there are not many domestic pharmaceutical packaging material manufacturers that have the ability to undertake this matter, such as Nanfang packaging

it is understood that national drug fairs, API fairs, medical device exhibitions and other professional exhibitions in the pharmaceutical industry are held every year, except for the independent exhibition of drug packaging materials, which are usually mixed in the exhibition of packaging materials. It can be seen that there are still some embarrassments in this rapidly developing industry. An industry insider who has been engaged in the production and operation of pharmaceutical packaging materials for many years believes that: through the efforts of enterprises and some local governments, two modes of the domestic pharmaceutical packaging industry have gradually emerged and are becoming the mainstream of the development of the industry: one is that giant enterprises such as Lianyungang Zhongjin pharmaceutical

packaging and Southern Packaging dominate each other; The other is Anbu in Guangdong, Xiongxian in Hebei, Jiangyin in in Jiangsu and Longgang in Zhejiang (the four are collectively referred to as the "four major production bases of flexible packaging in China"). Although the scale of local enterprises is generally small, there are a large number of them. These "small sampans" gather together, support each other, form a strong joint force, and occupy a considerable market share

who will eat the

20billion yuan cake? Getting part of it will make enterprises happy. However, the existing problems of many drug packaging enterprises make it impossible for drug packaging enterprises to be so proud of the market

"except for a few large-scale enterprises with relatively standardized quality management, there are many workshop enterprises in the overall pharmaceutical hollow capsule industry, and inferior products are full of them." Yuanxingrong, the R & D Manager of Shanghai chunzhitang biological products company, a health food enterprise that produces garlic oil soft capsules, told

Xinchang County, Zhejiang Province is known as the "hometown of capsules" in China, and its annual output once accounted for 1/3 of the country in the 1980s. However, among the 327 capsule production enterprises in Xinchang County, there are 299 unlicensed enterprises, 90% of which are in the "low, small and scattered" business situation, of which more than 40% of the capsule production enterprises belong to individual enterprises, and family workshops occupy the dominant position

these illegal manufacturers' unauthorized production of drug packaging materials without certification has brought a huge impact on those formal enterprises. According to insiders, the cost of the same composite membrane produced in the clean workshop is about 22000 yuan/ton; However, those produced in the "underground factory" cost no more than 18000 yuan/ton. In order to reduce product costs, some non-standard pharmaceutical enterprises secretly buy a large number of low-cost and low-quality products, which has seriously damaged the interests of many regular pharmaceutical packaging material manufacturers

liyong'an, general manager of Lianyungang Zhongjin pharmaceutical packaging Co., Ltd., also told: "although there is a huge market potential in the pharmaceutical packaging market, we still need to make a careful decision." Because the existing pictures in China show TECHNYL reg; Among the manufacturing enterprises of mechanical strength drug packaging materials that redx has formed (initially) and placed at 220 ℃ for 24 hours, most of them are township collective enterprises with small scale, low personnel quality, equipment, technology and management level, and unstable product quality, resulting in disorderly competition. Their company is seeking diversified development, turning to exploring packaging opportunities in the food industry, while the expansion of drug packaging production, It also needs to wait for the country to further rectify and standardize the market

characteristics are the way out

marketing experts pointed out that interactive personalized marketing has become the mainstream mode of marketing, and personalized consumption puts forward higher requirements for drug packaging design. In today's highly homogeneous products, the packaging of products also has the phenomenon of "isomorphism". In drug packaging, consumers are not concerned about fancy patterns, but whether their feelings are respected, whether the products have affinity, and whether they reflect the taste and lifestyle of the target group. Those pleasing to the eye and high-grade packaging are naturally favored. This requires designers to deeply live in the design of packaging, and pay attention to the grasp of human nature

in order to achieve a wider range of communication and have the ability of global recognition, the national style of drug packaging can not be ignored. With the acceleration of international trade integration, several listed companies at home and abroad have issued announcements that the drug packaging design should reach the international level as far as possible and have the ability of global recognition. However, packaging design cannot be globalized for the sake of globalization. Any packaging design has its inseparable national traditional cultural background. Only the nation is the world

Copyright © 2011 JIN SHI